Frequently Asked Questions

Retatrutide is a new experimental medication from the GLP-1/GIP/Glucagon agonist class, developed for the treatment of obesity and type 2 diabetes. It works by reducing appetite, slowing stomach emptying, and affecting hormones that regulate metabolism and body weight.

Retatrutide is primarily being developed for obesity treatment, with TRIUMPH trials focusing on weight loss in people with and without diabetes. It also significantly improves blood sugar control, reducing HbA1c by approximately 2% in diabetic patients, making it beneficial for both conditions.

FDA approval is expected in late 2027 or early 2028, with commercial launch following 1–3 months later. Eli Lilly must complete all seven TRIUMPH Phase 3 trials and submit a New Drug Application before the FDA's 10-month review process begins. Realistic availability: Q1–Q2 2028.

Two completed Phase 3 trials confirm retatrutide's efficacy: TRIUMPH-4 showed 28.7% average weight loss at 68 weeks, and TRIUMPH-1 confirmed 28.3% in 2,339 general obesity patients at 80 weeks. In a 104-week extension, patients reached 30.3%. This translates to approximately 70+ pounds for someone starting at 250 pounds. Results depend on dosage, diet, and exercise adherence.

Long-term sustainability depends on continued medication use and lifestyle changes. Semaglutide and tirzepatide have proven multi-year maintenance data. Retatrutide shows promise but lacks long-term studies beyond 80 weeks. All three require indefinite use — stopping treatment leads to weight regain within 2–3 weeks as appetite returns.

Retatrutide is a triple-hormone agonist targeting GLP-1, GIP, and glucagon receptors, while Semaglutide (Ozempic/Wegovy) only targets GLP-1. This triple mechanism produces 28.7% weight loss in trials compared to Semaglutide's 15%, nearly double the efficacy. The glucagon component enhances fat metabolism and energy expenditure.

Retatrutide activates three receptors (GLP-1, GIP, and glucagon), while Tirzepatide (Mounjaro/Zepbound) targets two (GLP-1 and GIP). In trials, Retatrutide produced 28.7% weight loss compared to Tirzepatide's 22.5%. The added glucagon component enhances fat burning and metabolic rate, creating superior weight loss results.

Clinical trials show Retatrutide achieves 28.7% weight loss at 68 weeks (TRIUMPH-4), while Tirzepatide produces 22.5% weight loss at 72 weeks (SURMOUNT-1). Retatrutide's triple-hormone mechanism provides approximately 6 percentage points more weight loss, making it the most effective obesity medication to date.

Yes. While Retatrutide, Semaglutide, and Tirzepatide can significantly reduce appetite and improve metabolism, combining them with a balanced diet, physical activity, and healthy routines maximizes results. Lifestyle changes also help sustain weight loss if the medication is discontinued.

Based on TRIUMPH-4 Phase 3 trial data, the most common side effects are nausea (43%), diarrhea (33%), vomiting (24%), and decreased appetite. Most side effects are gastrointestinal, occur during dose escalation in the first 8–12 weeks, and decrease significantly once patients reach their maintenance dose. Dysesthesia — a tingling or burning skin sensation — was also reported in 20.9% of patients, which is unique to retatrutide compared to other GLP-1 medications.

Based on available data, retatrutide appears safe for extended use. TRIUMPH-1 included a 104-week extension with no new safety signals reported. Discontinuation rates were 11.3% in TRIUMPH-1 and 18.2% in TRIUMPH-4 — comparable to or better than other approved obesity medications. Full long-term safety data beyond 104 weeks is not yet available, as the drug remains investigational.

Dysesthesia is an abnormal skin sensation — typically described as tingling, burning, or numbness — that occurs in some retatrutide patients. It was reported in 20.9% of patients in the TRIUMPH-4 trial, making it the most notable side effect unique to retatrutide compared to semaglutide or tirzepatide. In most cases it is mild to moderate and resolves on its own. It does not appear to be dangerous, but patients should inform their doctor if it occurs.

Most side effects peak during the dose escalation phase (weeks 4–12) and improve significantly once patients reach their maintenance dose of 9mg or 12mg. By weeks 16–24, the majority of patients report minimal side effects. The 11.3% discontinuation rate in TRIUMPH-1 suggests that most patients can tolerate retatrutide through the full treatment course. Patients who make it past week 16 rarely discontinue due to side effects.